90-60-8 Usage
Description
3,5-Dichlorosalicylaldehyde is an organic compound characterized by the presence of two chlorine atoms at the 3rd and 5th positions of the salicyaldehyde molecule. It is a derivative of salicylic aldehyde, which is a key component in the synthesis of various organic compounds and pharmaceuticals. Its chemical structure allows it to participate in a wide range of chemical reactions, making it a versatile building block in organic chemistry.
Uses
Used in Pharmaceutical Industry:
3,5-Dichlorosalicylaldehyde is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its unique structure allows it to be easily modified and incorporated into a variety of drug molecules, making it a valuable component in the development of new medications.
Used in Organic Chemistry:
3,5-Dichlorosalicylaldehyde is used as a versatile building block in organic chemistry for the preparation of various organic compounds. Its reactivity and ability to form a wide range of chemical bonds make it a useful starting material for the synthesis of complex organic molecules.
Used in the Preparation of Schiff Base Ligands:
3,5-Dichlorosalicylaldehyde is used as a starting material in the preparation of Schiff base ligands. Schiff bases are a class of compounds formed by the condensation of a primary amine with an aldehyde or ketone. These ligands are widely used in coordination chemistry, as they can form stable complexes with metal ions, making them useful in various applications, such as catalysis and the development of new materials.
Used in the Preparation of (RS)-3,5-Dichloro-2-[[(1-Phenylethyl)imino]methyl]Phenol:
3,5-Dichlorosalicylaldehyde is also used in the preparation of (RS)-3,5-dichloro-2-[[(1-phenylethyl)imino]methyl]phenol, a specific organic compound with potential applications in various fields. The synthesis of this compound demonstrates the versatility of 3,5-dichlorosalicylaldehyde as a starting material for the preparation of a wide range of organic compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 90-60-8 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 9 and 0 respectively; the second part has 2 digits, 6 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 90-60:
(4*9)+(3*0)+(2*6)+(1*0)=48
48 % 10 = 8
So 90-60-8 is a valid CAS Registry Number.
InChI:InChI=1/C7H4Cl2O2/c8-5-1-4(3-10)7(11)6(9)2-5/h1-3,11H
90-60-8Relevant articles and documents
Phosphine-catalyzed sequential (2+3)/(2+4) annulation of γ-vinyl allenoates: Access to the synthesis of chromeno[4,3-: B] pyrroles
Huang, You,Li, Xiaohu
supporting information, p. 9934 - 9937 (2021/10/12)
A phosphine-catalyzed cascade (2+3)/(2+4) cyclization reaction of γ-vinyl allenoates with aldimine esters has been developed to provide a series of chromeno[4,3-b]pyrrole derivatives that contain three contiguous stereogenic centers. The method gives a good yield, excellent chemoselectivity and diastereoselectivity under mild conditions.
Synthesis characterization and cytotoxicity studies of platinum(II) complexes with reduced amino pyridine schiff base and its derivatives as ligands
Li, Li-Jun,Yan, Qin-Qin,Liu, Guo-Jun,Yuan, Zhen,Lv, Zhen-Hua,Fu, Bin,Han, Yan-Jun,Du, Jian-Long
, p. 1081 - 1089 (2017/05/29)
A series of reduced amino pyridine Schiff base platinum(II) complexes were prepared as potential anticancer drugs, and characterized by NMR, IR spectroscopy, elemental analysis, and molar conductivity. UV and CD results showed the binding mode between these compounds and salmon sperm DNA may be intercalation. The cytotoxicity of these complexes was validated against A549, Hela, and MCF-7 cell lines by MTT assay. Some complexes exhibited better cytotoxic activity than cisplatin against Hela and MCF-7 cell lines.
NO-RELEASING NITROOXY-CHROMENE CONJUGATES
-
Paragraph 0295; 0296, (2016/12/16)
The present invention provides NO-releasing nitrooxy-alkylenyl-linked-chromene conjugates, having the structure of Formula (1) wherein R1, R2, R3, R4, X, and L are as defined in the detailed description; pharmaceutical compositions comprising at least one compound o Formula (I); and methods useful for healing wounds, preventing and treating cancer and treating actinic keratosis, cystic fibrosis, and acne, using a compound of Formula (1).
